Gold Prices Surge 7% as Dollar Falls, Fed Rate Hike Bets Ease 
Oil Prices Surge as Iran Hormuz Restrictions Renew Supply Fears 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Brazil Cuts Selic Rate to 14% as Inflation Eases but Risks Persist 
Trump Unveils $3 Billion U.S. Critical Minerals Push 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Asian Currencies Hold Steady as US Dollar Nears Seven-Week Low Ahead of Key Jobs Data 
China Trade Surplus Beats Forecasts in July as Exports Stay Strong 
US Dollar Gains as Iran Tensions, Fed Rate Hike Bets Rise 
Asian Stocks Mixed as Chip Selloff Hits KOSPI, Nikkei Ahead of US Jobs Data 
China Exports Beat July Forecasts as AI Demand Fuels High-Tech Trade 
Singapore Says One-Third of U.S. Exports Hit by New 12.5% Tariff 
Asian Stocks Cautious Ahead of US Jobs Data as Oil Rises 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Daewoong’s Nabota was banned by the U.S. International Trade Commission late last year. The agency imposed a 21-month import and sale ban on the South Korean company’s botulinum toxin product brand.
The prohibition resulted from the verdict handed down by the ITC regarding Medytox’s 5-year legal battle against Daewoong Pharmaceutical. Apparently, the commission ruled in favor of the Gangnam-gu-based biopharmaceutical company. The two Korean firms are battling in court over the misappropriation of trade secrets complaints.
ITC revokes ban on Daewoong’s Nabota
This week, the US ITC has lifted the restriction on Daewoong’s botulinum toxin products. This means the firm can now resume the sale and import of its Nabota products that is also known as Jeuveau, in the U.S.
The Korea Herald reported that the latest decision would let Evolus, Daewoong Pharma’s partner based in the United States, to start selling Nabota in the region again. In any case, the ban was lifted after Medytox, Evolus, and AbbVie, Allergan’s parent company, agreed to resolve their dispute in February.
As part of the deal, the three corporations will also dissolve all the remaining cases at the ITC, including the sale of Nabota in the U.S. and other countries where Evolus has licensing rights.
How the companies settled the dispute
Moreover, it was revealed that Evolus agreed to pay Medytox and Allergan $35 million that will be paid in a series of lump sums in the span of two years. The Daewoong partner has to pay royalties to Medytox and Allergan based on Nabota’s net sales for 21 months. After this, Evolus will be paying royalties to Medytox alone.
Allergan is also involved in the case of Daewoong because botulinum toxin is the main component in Botox, a type of treatment for wrinkles. Allergan is the company that sells Botox.
Meanwhile, as per Pulse News, Daewoong Pharmaceutical Co.’s shares have increased on Tuesday, May 4. The numbers have jumped by 5.93 percent to close at ₩134,000 or around $119.37. This figure is expected to increase now that Nabota is being allowed to be sold again in the United States further.
